Have a feature idea you'd love to see implemented?
Let us know!
BCTX BriaCell Therapeutics Corp
Price (delayed)
$0.39
Market cap
$17.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
$11.45M
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
Highlights
The company's equity rose by 48% YoY
BriaCell Therapeutics's quick ratio has plunged by 91% YoY
The net income has decreased by 27% YoY
Key stats
What are the main financial stats of BCTX
Market
Valuations
Earnings
Shares outstanding
44.2M
Market cap
$17.24M
Enterprise value
$11.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$16.77M
EBIT
-$2.31M
EBITDA
-$2.21M
Free cash flow
-$23.93M
Per share
Balance sheet
Liquidity
EPS
-$0.89
EPS diluted
-$0.89
Free cash flow per share
-$0.9
Book value per share
$0.1
Revenue per share
$0
TBVPS
$0.38
Total assets
$10.41M
Total liabilities
$6.7M
Debt
$0
Equity
$3.71M
Working capital
$3.23M
Debt to equity
0
Current ratio
1.65
Quick ratio
1.16
Net debt/EBITDA
2.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-193.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-42.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCTX stock price
How has the BriaCell Therapeutics stock price performed over time
Intraday
-2.82%
1 week
-12.75%
1 month
-40.91%
1 year
-91.12%
YTD
-30.97%
QTD
-30.97%
Financial performance
How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.98M
Net income
-$16.77M
Gross margin
N/A
Net margin
N/A
The net income has decreased by 27% YoY
The company's operating income fell by 14% YoY but it rose by 10% QoQ
Growth
What is BriaCell Therapeutics's growth rate over time
Valuation
What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
3.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 3.5% year-on-year
The company's equity rose by 48% YoY
Efficiency
How efficient is BriaCell Therapeutics business performance
Dividends
What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCTX.
Financial health
How did BriaCell Therapeutics financials performed over time
The total assets is 55% greater than the total liabilities
BriaCell Therapeutics's current ratio has shrunk by 91% YoY
BriaCell Therapeutics's quick ratio has plunged by 91% YoY
The debt is 100% smaller than the equity
The company's equity rose by 48% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.